STAT

JANUARY 8, 2024

Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion, picking up a company specializing in targeted chemotherapy treatments — one of the hottest areas of cancer drug development.     The deal, disclosed as the biopharma field marked the first day of the annual J.P.

Chemotherapy 127

Chemotherapy 127

Pharmacy Times

SEPTEMBER 16, 2024

Abstracts from the OrigAMI-1 and MARIPOSA-2 trials indicated the treatment benefits of amivantamab-vmjw and chemotherapy in multiple cancer indications.

Chemotherapy 50

Chemotherapy 50

PharmTech

JUNE 23, 2025

Zemcelpro is used to treat patients that require allogeneic hematopoietic stem cell transplantation following chemotherapy or radiotherapy when no other type of suitable donor cells is available. Two generic drugs were also approved.

Dosage 59

Dosage Chemotherapy Packaging 59

European Pharmaceutical Review

JUNE 27, 2024

Immunotherapy in oncology “The addition of pembrolizumab to chemotherapy represents a new frontline therapeutic option for patients with primary advanced or recurrent endometrial carcinoma” Moreover, last week saw US regulatory approval of a combination treatment for endometrial cancer : KEYTRUDA (pembrolizumab) plus chemotherapy.

Chemotherapy 64

Chemotherapy FDA 64

Hospital Pharmacy Europe

JANUARY 24, 2024

The final draft guidance from NICE recommends talazoparib for the treatment of adults with BRCA 1 or 2 mutated HER2-negative locally advanced or metastatic breast cancer after prior chemotherapy. Evidence from a clinical trial showed that talazoparib increases how long people live without their cancer getting worse compared with chemotherapy.

Chemotherapy 101

Chemotherapy Hospitals 101

Pharmaceutical Technology

DECEMBER 11, 2024

The prevailing treatment paradigm for newly diagnosed multiple myeloma (NDMM) patients who have received autologous stem cell transplantation (SCT) primarily consists of chemotherapy or Johnson & Johnsons (J&J) Darzalex in combination with chemotherapy.

Chemotherapy 59

Chemotherapy 59

Pharmacy Times

DECEMBER 14, 2024

Adding anthracyclines to chemotherapy may improve survival in high-risk breast cancer patients.

Chemotherapy 65

Chemotherapy 65

European Pharmaceutical Review

OCTOBER 25, 2024

The biologic ZL-1310 is being investigated in an ongoing Phase Ia/Ib study in these patients who have had at least one platinum-based chemotherapy regimen. This initial data on ZL-1310 was presented this week at the EORTC-NCI-AACR (ENA) Symposium 2024.

Chemotherapy 97

Chemotherapy Compounding Immunization 97

Pharmaceutical Technology

SEPTEMBER 6, 2022

Updated using the pre|CISION technology, AVA6000 is a kind of generic chemotherapy doxorubicin. By 2024, doxorubicin is anticipated to have a market size of $1.38bn and is extensively utilised as a part of the standard of care in various types of cancers. . It also boosts the drug’s safety, tolerability and efficacy.

FDA 98

FDA Chemotherapy 98

STAT

APRIL 11, 2024

Medicare actuaries expect the drug, which is called Leqembi and sold by Eisai in partnership with Biogen, to cost the traditional Medicare program around $550 million in 2024. That is projected to increase to $3.5 billion in 2025 for the entire Medicare program, a spokesperson for the Centers for Medicare and Medicaid Services confirmed.

Chemotherapy 108

Chemotherapy Immunization 108

pharmaphorum

AUGUST 31, 2022

In May, a Phase 2 study started, comparing Kaiku’s electronic patient-reported outcome (ePRO) approach to evaluating immune-related adverse events to the standard model of care in cancer patients treated with checkpoint inhibitor drugs, with results due towards the end of 2023 or in early 2024.

Chemotherapy 116

Chemotherapy Immunization Hospitals 116

European Pharmaceutical Review

FEBRUARY 21, 2024

TAGRISSO as a combination treatment with chemotherapy was recently approved in the US, based on data from the FLAURA2 Phase III trial. Results from a Phase III trial in the neoadjuvant setting are expected later in 2024. According to AstraZeneca, the small molecule treatment TAGRISSO is also being investigated in two Phase III trials.

Chemotherapy 105

Chemotherapy 105

European Pharmaceutical Review

MAY 20, 2024

This includes antibody production, chemotherapy drug and linker synthesis, conjugating the drug-linker to the antibody, as well as filling of the completed ADC substance, AstraZeneca confirmed. The pharmaceutical firm stated that it is planning to begin the design and construction of the manufacturing facility by the end of 2024.

Chemotherapy 98

Chemotherapy 98

STAT

JULY 31, 2023

… House Republicans have drafted drug-shortage legislation that differs significantly from the approach Democrats propose to stem shortages of chemotherapies and other critical medicines that hospitals typically use , STAT explains. Republicans We value your postcards and telegrams.

FDA 97

FDA Chemotherapy Hospitals 97

PharmExec

DECEMBER 5, 2023

The FDA assigned a PDUFA date of April 5, 2024 for Opdivo (nivolumab) plus cisplatin-based chemotherapy for the first-line treatment of adults with unresectable or metastatic urothelial carcinoma.

FDA 52

FDA Chemotherapy 52

pharmaphorum

MARCH 25, 2022

facility at Kent Science Park (KSP) in Sittingbourne is due to open in 2024, and when fully operational will create more than 100 new highly skilled jobs. If trials are successful, nabiximols could become one of the first additions to treatment for glioblastoma patients since temozolomide chemotherapy in 2007. The 60,000 sq.

Chemotherapy 98

Chemotherapy 98

Pharmacy Times

JUNE 27, 2025

Because of its aggressive nature, MCL is typically treated with combination chemotherapy at diagnosis. 5 Phase 3 ECHO Trial: A New Frontline Option The approval was supported by data from the phase 3 ECHO trial (NCT02972840), presented at the 2024 European Hematology Association Hybrid Congress. June 21, 2024. Hemasphere.

50

50

Hospital Pharmacy Europe

MARCH 14, 2024

The monoclonal antibody dostarlimab (brand name Jemperli) has been recommended by the National Institute for Health and Care Excellence (NICE) for use in combination with platinum-based chemotherapy for eligible patients with endometrial cancer. Publication of the final guidance is expected on 3 April 2024.

Chemotherapy 52

Chemotherapy Hospitals 52

pharmaphorum

JANUARY 23, 2023

The drug achieved an impressive 84% overall survival rate over 18 months in patients with advanced GEA who received it as a first-line therapy in combination with chemotherapy, according to data from the open-label study. GEA is the fifth most common cancer worldwide, and around one in five patients have tumours that are HER2-positive.

Chemotherapy 52

Chemotherapy Labelling 52

European Pharmaceutical Review

AUGUST 12, 2024

The deal is anticipated to be finalised in Q3 of 2024. It is the first anti-PD-1 therapy approved for use together chemotherapy in adults who have primary advanced or recurrent endometrial carcinoma, regardless of mismatch repair status.

Research Laboratories 59

Research Laboratories Chemotherapy FDA 59

Pharmaceutical Technology

MAY 2, 2023

Part of the proceeds will be used to fund our wholly owned pamrevlumab programme as we anticipate five Phase III readouts to occur before mid-2024.” FibroGen CEO Enrique Conterno stated: “With the current momentum across our development programmes, this financing strengthens our balance sheet.

Chemotherapy 52

Chemotherapy 52

Pharmaceutical Technology

JUNE 15, 2023

PEMRYDI RTU is indicated as an initial treatment, along with pembrolizumab and platinum chemotherapy, for metastatic non-squamous non-small cell lung cancer patients with no epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumour aberration.

FDA 52

FDA Chemotherapy 52

Hospital Pharmacy Europe

OCTOBER 14, 2024

On 31 May 2024, Dr Kunene led a team to administer the very first personalised vaccine against colorectal cancer in England as part of the pioneering NHS Cancer Vaccine Launch Pad (CVLP) initiative. Another treatment combination is chemotherapy with zolbetuximab – an antibody directed against claudin 18.6.

Vaccines 52

Vaccines Chemotherapy Hospitals Immunization 52

European Pharmaceutical Review

DECEMBER 28, 2023

As a result, when the patient’s lymphoma relapses after treatment with chemotherapy, BV and CPIs, there are no effective treatment alternatives for these patients. We have now already treated the first patients and are expecting the first results from this study in the first half of 2024. 

Immunization 84

Immunization Chemotherapy Medical Schools FDA 84

PharmaShots

JUNE 19, 2023

This test can help veterinary professionals to detect kidney injury before it affects kidney function & may result in better patient outcomes The test will be conducted at IDEXX Reference Laboratories in the US & Canada with plans to roll out in the EU in 2024. IDEXX’s suite of kidney health diagnostics incl.

Chemotherapy 40

Chemotherapy 40

Pharmacy Times

JUNE 27, 2025

After learning of his diagnosis, our relationship shifted from small talk at school events to detailed discussions in an infusion center setting about chemotherapy, immunotherapy, clinical trials, alternative medicines, and anticipated adverse effects. January 17, 2024. 2024;25(1):336. doi:10.1186/s13063-024-08174-x 7. Pharmacy Times.

50

50

pharmaphorum

MARCH 8, 2022

In the study, Trodelvy (sacituzumab govitecan) met its objective of reducing progression-free survival in patients with HR-positive, HER2-negative metastatic breast cancer who received multiple lines of prior treatment – including endocrine drugs, CDK4/6 inhibitors and two to four lines of chemotherapy.

Chemotherapy 52

Chemotherapy Documentation Labelling 52

European Pharmaceutical Review

JULY 18, 2024

1,2 This is especially important in forms of cancer where chemotherapy remains the main treatment option. Because ADCs offer a good way to specifically deliver an effective treatment to tumour systems, this could be an improvement on the systemic impact of chemotherapy. Rise of Antibody-Drug Conjugates: The Present and Future.

Chemotherapy 59

Chemotherapy FDA 59

pharmaphorum

OCTOBER 10, 2022

The study showed that the combination has the potential to “provide a safer and better tolerated alternative” to the use of PD-1/PD-L1 drugs plus chemotherapy in first-line NSCLC, the current standard of treatment, according to Dr Chris Redhead of Goetz Partners. month mPFS with Keytruda plus chemo, with fewer side effects.

Chemotherapy 59

Chemotherapy FDA 59

pharmaphorum

DECEMBER 5, 2022

The trial tested Jemperli given alongside chemotherapy with carboplatin and paclitaxel, followed by Jemperli alone, to a control group given placebo plus chemo followed by placebo.

Chemotherapy 52

Chemotherapy Labelling FDA 52

Pharmaceutical Technology

FEBRUARY 17, 2023

In 2021, Amgen agreed to conduct a Phase II study (NCT04933695), which is supposed to complete in May 2024, according to Clinicaltrials.gov. The demand came amid concerns that the drug causes a slew of side effects such as nausea, diarrhea, and liver issues.

Dosage 115

Dosage FDA Pharmaceutical Companies Pharmaceutical Companies 115

pharmaphorum

SEPTEMBER 27, 2021

There were also 7% fewer chemotherapy courses delivered, and 13% fewer radiotherapy procedures. Expanding MRI scan capacity by 10% could clear the full MRI backlog in the NHS by 2024 instead of 2040, according to the report. billion in new funding for NHS England announced earlier this month by the government.

Chemotherapy 45

Chemotherapy Hospitals 45

NF2 BioSolutions

OCTOBER 13, 2023

Oscar has started attending a youth group here in Nottingham – they meet every week and the other children that go (varying age ranges) are kids that are all have chronic illnesses or going through treatment like Avastin, immunotherapy, chemotherapy etc. Check out the website today and find out what they can offer!

Hospitals 59

Hospitals Chemotherapy 59

Pharmacy Times

JUNE 25, 2025

Benmelstobart (TQB2450; Chia Tai Tianqing Pharmaceutical Group Co, Ltd) in combination with chemotherapy followed by sequential combination with anlotinib (Catequentinib; Advenchen Laboratories) led to significant improvements in progression-free survival (PFS), with a manageable safety profile. months versus 7.79 months with tislelizumab.

Chemotherapy 50

Chemotherapy Compounding Pharmacies Immunization Compounding 50

Blog: Ask a Student Pharmacist

JUNE 21, 2023

Particularly, we devote a large portion of our research to identifying novel compounds that impact cellular uptake or inhibit drug efflux - the most common mechanism underlying acquired drug resistance in cancer, pinpointing the transporters or targets involved in these processes, and evaluating regimens to produce desirable anti-cancer responses.

Compounding 40

Compounding Chemotherapy Immunization 40

The Thyroid Pharmacist

SEPTEMBER 20, 2024

Chemotherapy agents: Chemotherapy agents can lead to constipation in a variety of ways such as slowing the movements of the intestinal tract or creating inflammation that disrupts digestive function. Accessed September 6, 2024. Accessed September 17, 2024. freece.com. [11] 11] Bhattacharjee B, Upadhyay S, Ghosh J.

Health and Personal Care Stores 84

Health and Personal Care Stores Chemotherapy Immunization Compounding 84

Pharmacy Times

JUNE 19, 2025

1 Biomarker testing is relatively new in the treatment landscape for NSCLC but has proven incredibly important for personalizing patient care, transforming from a generic chemotherapy approach to a highly personalized, genomically driven treatment strategy. For advanced disease, chemotherapy was the standard.

Chemotherapy 65

Chemotherapy Compounding Pharmacies Hospitals Immunization 65